{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:07:01Z","timestamp":1784239621810,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.arteri.2026.500957","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:44:24Z","timestamp":1784238264000},"page":"500957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First real-world experience with inclisiran in Spain: Efficacy, safety, and prescription patterns in clinical practice"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6486-4782","authenticated-orcid":false,"given":"Alvaro","family":"Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Alonso-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Hayes Meizoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Blanco-Echevarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Tello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2026.500957_bib0060","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.arteri.2026.500957_bib0065","first-page":"310","article-title":"Uso de nuevas terapias hipolipemiantes en la pr\u00e1ctica cl\u00ednica. Consenso EC\/SEA\/SEEN\/SEMFYC\/SEMERGEN\/SEMG\/SEN\/SEACV\/S.E.N.","volume":"59","author":"Vivas","year":"2024","journal-title":"REC: CardioClinics"},{"key":"10.1016\/j.arteri.2026.500957_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2026.500957_bib0080","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2026.500957_bib0085","unstructured":"First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population \u2013 Clinical Therapeutics. https:\/\/www.clinicaltherapeutics.com\/article\/S0149-2918(23)00476-9\/fulltext. Accessed 14 October 2025."},{"key":"10.1016\/j.arteri.2026.500957_bib0090","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","article-title":"Real-world efficacy and safety of inclisiran: a single-country, multicenter, observational study (CHOLINET Registry)","volume":"85","author":"Gargiulo","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2026.500957_bib0095","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","article-title":"First clinical experiences with inclisiran in a real-world setting","volume":"17","author":"Mulder","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2026.500957_bib0100","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","article-title":"High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.arteri.2026.500957_bib0105","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1016\/j.jacl.2024.05.003","article-title":"Lipid-lowering therapy with inclisiran in the real-world setting: initial data from a national health care service","volume":"18","author":"Naoum","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2026.500957_bib0115","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.eprac.2023.03.004","article-title":"Statin intolerance: a review and update","volume":"29","author":"Tsushima","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.arteri.2026.500957_bib0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jacl.2025.10.066","article-title":"Reduction of visit-to-visit LDL-C intraindividual variability in patients treated with PCSK9 inhibitors and inclisiran vs standard lipid-lowering therapy","volume":"20","author":"Cesaro","year":"2026","journal-title":"J Clin Lipidol"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916826000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916826000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:44:26Z","timestamp":1784238266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916826000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":11,"alternative-id":["S0214916826000665"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500957","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First real-world experience with inclisiran in Spain: Efficacy, safety, and prescription patterns in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2026.500957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500957"}}